We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Biosimilar Act Trumps State Laws, Fed. Circ. Rules

Law360, New York (December 14, 2017, 11:01 AM EST) -- The federal biosimilars act prevents drugmakers from using state laws to punish rivals for withholding information about copycat products, the Federal Circuit ruled Thursday.

The unanimous ruling sided with Sandoz Inc. over Amgen Inc. in a long-running and high-stakes battle that has laid out ground rules for the fledgling biosimilars industry. At issue was whether Amgen could use state laws — such as California’s unfair competition law — to compel disclosure of approval applications and manufacturing information that need not be divulged under the Biologics Price...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Amgen Inc. et al v. Sandoz Inc. et al


Case Number

3:14-cv-04741

Court

California Northern

Nature of Suit

Patent

Judge

Richard Seeborg

Date Filed

October 24, 2014


Case Title

Amgen Inc. v. Sandoz Inc.


Case Number

15-1499

Court

Appellate - Federal Circuit

Nature of Suit

830 Patent Infringement (Fed. Question)

Date Filed

March 27, 2015

Law Firms

Companies

Government Agencies

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.